Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment
Isofol Medical AB today announced that the first dose cohort with Modufolin® as rescue therapy, after treatment with two cycles of HDMTX, fulfilled the study objectives in the ongoing Phase I/II open-label, multicenter clinical trial, ISO-MTX-003. In total four patients with osteosarcoma have successfully completed their treatment with Modufolin® at 15 mg/m2. Isofol is now …
